The efficiency and safety of high-dose vitamin C in patients with COVID-19: a retrospective cohort study
| Autor: | Min Xu, Dengfeng Gao, Lv Lv, Yonghong Guo, Huiyun Yang, Gang Wang, Jianrui Lv, Shouping Gong, Ziwei Lu, Fuxue Deng, Wei Jiang, Guozhi Xia, Dexin Zhang, Xiao-Rong Ma |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
safety Aging medicine.medical_specialty Coronavirus disease 2019 (COVID-19) Ascorbic Acid Loading dose Gastroenterology Sepsis coronavirus disease 2019 Internal medicine Medicine Humans In patient Adverse effect Aged Retrospective Studies Vitamin C Dose-Response Relationship Drug business.industry SARS-CoV-2 COVID-19 Retrospective cohort study Cell Biology Vitamins Middle Aged medicine.disease Ascorbic acid mortality COVID-19 Drug Treatment Treatment Outcome Female business Research Paper |
| Zdroj: | Aging (Albany NY) |
| ISSN: | 1945-4589 |
| Popis: | Background: The inflammatory reaction is the main cause of acute respiratory distress syndrome and multiple organ failure in patients with Coronavirus disease 2019, especially those with severe and critical illness. Several studies suggested that high-dose vitamin C reduced inflammatory reaction associated with sepsis and acute respiratory distress syndrome. This study aimed to determine the efficacy and safety of high-dose vitamin C in Coronavirus disease 2019. Methods: We included 76 patients with Coronavirus disease 2019, classified into the high-dose vitamin C group (loading dose of 6g intravenous infusion per 12 hr on the first day, and 6g once for the following 4 days, n=46) and the standard therapy group (standard therapy alone, n=30). Results: The risk of 28-day mortality was reduced for the high-dose vitamin C versus the standard therapy group (HR=0.14, 95% CI, 0.03-0.72). Oxygen support status was improved more with high-dose vitamin C than standard therapy (63.9% vs 36.1%). No safety events were associated with high-dose vitamin C therapy. Conclusion: High-dose vitamin C may reduce the mortality and improve oxygen support status in patients with Coronavirus disease 2019 without adverse events. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|